BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma

Leukemia. 2006 Jul;20(7):1313-5. doi: 10.1038/sj.leu.2404228. Epub 2006 Apr 13.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • B-Cell Activating Factor / physiology*
  • Cell Survival / physiology
  • Humans
  • Immunoglobulin Fc Fragments / genetics
  • Immunoglobulin Fc Fragments / therapeutic use
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / pathology*
  • Osteoclasts / physiology
  • Transmembrane Activator and CAML Interactor Protein / genetics
  • Transmembrane Activator and CAML Interactor Protein / therapeutic use*
  • Tumor Necrosis Factor Ligand Superfamily Member 13 / physiology*

Substances

  • B-Cell Activating Factor
  • Immunoglobulin Fc Fragments
  • TNFSF13B protein, human
  • Transmembrane Activator and CAML Interactor Protein
  • Tumor Necrosis Factor Ligand Superfamily Member 13